Development Pipeline

Our novel, biomarker-driven product pipeline includes targeted oncology and tumor microenvironment therapies that focus on key drivers of cancer progression.

Development Pipeline

Our biomarker-driven product pipeline includes targeted oncology and tumor microenvironment therapies that focus on key drivers of cancer.

Ikena is leveraging its core capabilities in structural biology-guided chemistry, deep cancer biology, translational sciences, and clinical development to build a pipeline of targeted oncology and tumor microenvironment therapies that address a broad range of solid tumors. We generate and validate biomarkers in order to enrich our programs for patients who we believe may be most likely to benefit from treatment with our product candidates. We then design clinical trials with the potential to demonstrate rapid proof-of-concept based on these biomarker strategies for the treatment of patients in disease indications with high unmet medical needs.
Program
Target
Indication
  • Disc.
  • Pre-Cli.
  • Ph1
  • Ph2

Targeted Oncology

IK-930 IK-930
TEAD
Hippo-mutated cancers
TEAD
Hippo-mutated cancers
  • Pre-C
RAS Signaling RAS Signaling
ERK5
KRAS-mutated cancers
ERK5
KRAS-mutated cancers
  • Disc.
RAS Pathway RAS Pathway
Multiple
Solid Tumors
Multiple
Solid Tumors
  • Disc.

Tumor Microenvironment

IK-1751 IK-1751
AHR
Biomarker-enriched bladder cancer
AHR
Biomarker-enriched bladder cancer
  • PH1
BMS Collaboration
IK-4121 IK-4121
Kynurenine
Undisclosed
Kynurenine
Undisclosed
  • Pre-C
BMS Collaboration
EP4
Biomarker-enriched MSS CRC
  • PH1

Explore the scientific research that supports our pipeline.